90Y TARE and Treatment-Associated Data
| Characteristic | 90Y resin group (n = 41) | 90Y glass group (n = 36) | P |
| 90Y TARE | |||
| 90Y administered activity (GBq) | 1.80 (1.35–2.50) | 1.81 (1.21–2.93) | 0.52 |
| TV based on 99mTc-MAA SPECT/CT (cm3) | 220 (125–640) | 183 (100–381) | 0.26 |
| 90Y administered activity per unit of TV (MBq/cm3) | 7.3 (5–12) | 8.4 (6.5–16.3) | 0.04 |
| 90Y tumor liver absorbed dose (Gy) | 160 (115–254) | 242 (174–316) | 0.13 |
| 90Y normal liver absorbed dose (Gy) | 36 (27–50) | 45 (34–58) | 0.09 |
| Lobar | 22 (53.7) | 19 (52.8) | 0.94 |
| Bilobar | 10 (24.4) | 3 (8.3) | 0.06 |
| Segmental | 2 (4.9) | 11 (30.6) | 0.003 |
| Partial lobe | 1 (2.4) | 0 (0) | 0.35 |
| Lobar and segmental | 4 (9.8) | 2 (5.6) | 0.49 |
| Lobar and partial lobe | 2 (4.9) | 1 (2.8) | 0.64 |
| Treatment before 90Y TARE | |||
| Targeted therapy | 3 (7.3) | 2 (5.6) | 0.75 |
| Embolization | 4 (9.8) | 2 (5.6) | 0.49 |
| TACE | 13 (31.7) | 6 (16.7) | 0.13 |
| Radiofrequency ablation | 8 (19.5) | 9 (25) | 0.56 |
| Ethanol ablation | 2 (4.9) | 1 (2.8) | 0.64 |
| Treatments after 90Y TARE | |||
| Targeted therapy | 6 (14.6) | 4 (11.1) | 0.65 |
| Hepatectomy | 1 (2.4) | 0 (0) | 0.35 |
| Embolization | 1 (2.4) | 0 (0) | 0.35 |
| TACE | 7 (17.1) | 4 (11.1) | 0.46 |
| Radiofrequency ablation | 3 (7.3) | 4 (11.1) | 0.56 |
| Ethanol ablation | 0 (0) | 1 (2.8) | 0.28 |
| Chemotherapy | 1 (2.4) | 0 (0) | 0.35 |
| Second TARE | 1 (2.4) | 1 (2.8) | 0.93 |
TACE = transarterial.
Values are median, with 25th–75th interquartile range in parentheses, or n, with percentages in parentheses.